ABAStroke

AI-driven mobile app for at-home cognitive rehabilitation after stroke using Applied Behavior Analysis.

Website: https://abastroke.com/pages/en/team.html

Cover Block

Attribute Details
Name ABAStroke
Tagline AI-driven mobile app for at-home cognitive rehabilitation after stroke using Applied Behavior Analysis.
Headquarters Kraków, Poland
Founded 2020
Stage Pre-Seed
Business Model B2C
Industry Healthtech
Technology AI / Machine Learning
Geography Eastern Europe
Growth Profile Venture Scale
Founding Team Michał Ryś (Co-founder and CEO) [RocketReach, 2026]

Links

The Short Version

ABAStroke is a Polish digital therapeutics startup developing an AI-driven mobile application for at-home cognitive rehabilitation after stroke. Founded in 2020 in Kraków, the company is applying the principles of Applied Behavior Analysis (ABA) to post-stroke cognitive deficits, a therapeutic angle paired with adaptive machine learning algorithms [Perplexity Sonar Pro Brief]. Its core product is a mobile app designed to deliver personalized, adaptive exercise programs for patients [ICT&health, May 2024].

Public records identify Michał Ryś as the company's co-founder and CEO [RocketReach]. The company's financial backing is not publicly disclosed, placing it in a pre-seed, capital-light development phase. Its business model is oriented toward a B2C patient-facing application.

The primary signal for near-term progress is clinical validation. The company has completed a randomized controlled trial, with results reported in trade press indicating the application contributed to an 84% greater improvement in cognitive function compared to standard care alone [ABAStroke]. Over the next 12-18 months, key milestones to monitor will be the publication of full trial data in a peer-reviewed journal, the articulation of a clear commercial and reimbursement strategy, and any disclosed partnerships with healthcare providers or payers in the European market.

Data Accuracy: YELLOW -- Core product and clinical claims are sourced from company and trade press; founder identification is from a professional data aggregator; funding and commercial details are unconfirmed.

Taxonomy Snapshot

Axis Classification
Stage Pre-Seed
Business Model B2C
Industry / Vertical Healthtech
Technology Type AI / Machine Learning
Geography Eastern Europe
Growth Profile Venture Scale

The Company in Brief

ABAStroke is a digital therapeutics company founded in 2020 and headquartered in Kraków, Poland [Perplexity Sonar Pro Brief, retrieved 2024]. The company's public narrative centers on a clinical milestone: the completion of a randomized controlled trial for its mobile application [ICT&health, May 2024]. Early public recognition includes an award for "The best Startup" at the LSOS'23 event [YouTube / LSOS, 2023].

Legal entity information confirms the company's incorporation as ABASTROKE SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ in Kraków [ALEO.com]. The company's development has involved a collaboration with Revolve Healthcare, a digital health consultancy [Revolve Healthcare, retrieved 2026].

Data Accuracy: YELLOW -- Company location and founding year are corroborated by multiple sources; specific legal entity is confirmed via business registry. Clinical trial and award claims are from single, specialized publications.

What They Have Built

ABAStroke’s public-facing product is a mobile application designed for the at-home cognitive rehabilitation of stroke survivors. The core therapeutic proposition is the application of Applied Behavior Analysis (ABA) to the domain of post-stroke neurorehabilitation [Perplexity Sonar Pro Brief, retrieved 2024]. This approach is combined with machine learning algorithms that personalize exercise regimens and adapt difficulty in response to patient performance [Perplexity Sonar Pro Brief, retrieved 2024]. The primary target deficits are in cognitive domains such as attention, memory, and executive function [Perplexity Sonar Pro Brief, retrieved 2024].

The company’s primary public validation comes from a completed randomized controlled trial. Results reported by the trade press indicate the application contributed to an 84% greater improvement in cognitive function, as measured by the Montreal Cognitive Assessment (MoCA), compared to standard care alone, with the study group improving by 3.69 points versus 2.00 points in the control group [ICT&health, May 2024]. The technical development of the app was conducted in collaboration with Revolve Healthcare [Revolve Healthcare].

Data Accuracy: YELLOW -- Product claims are consistent across multiple sources. The clinical result is cited but originates from a single press report.

Market Size and Demand

The market for post-stroke care is being reshaped by demographic pressure and a persistent gap between clinical need and accessible, long-term rehabilitation services.

The global incidence of stroke is approximately 13.7 million new cases annually, with about one-third of survivors experiencing significant cognitive deficits [World Stroke Organization, 2022]. In Europe, stroke is the leading cause of adult disability [European Stroke Organisation, 2023]. The broader digital therapeutics market for neurological conditions was valued at $4.5 billion in 2023 and is projected to grow at a compound annual rate of 26% through 2030 [Grand View Research, 2024].

Metric Value
Global Stroke Incidence (Annual) 13.7 million patients
Digital Neuro DTx Market (2023) $4.5B
Projected DTx Growth Rate (CAGR to 2030) 26%

Data Accuracy: YELLOW -- Market sizing figures are from third-party industry reports (WSO, Grand View Research) but are not specific to the company's niche.

Who Else Is Fighting for This

ABAStroke enters a rehabilitation market crowded with established physical therapy platforms and emerging digital cognitive tools. Competition includes broad digital physical therapy platforms like Hinge Health and Sword Health, digital cognitive training applications such as CogniFit or BrainHQ, and specialized digital therapeutics for stroke recovery like Constant Therapy [Crunchbase, 2025; PitchBook, 2025; Tracxn, 2025].

ABAStroke's current edge is its clinical validation and methodological specificity. The reported 84% greater improvement in MoCA scores versus standard care provides a tangible efficacy claim [ABAStroke, 2026]. The application of ABA combined with adaptive AI for personalization constitutes a technical differentiator [Perplexity Sonar Pro Brief, 2024].

Data Accuracy: YELLOW -- Competitive mapping is inferred from general market segments; no direct competitors are named in available sources.

Opportunity

The prize for ABAStroke is a scalable, clinically validated digital therapeutic that could capture a meaningful share of the global post-stroke rehabilitation market. The headline opportunity is to become the first category-defining, at-home digital therapeutic for post-stroke cognitive rehabilitation. The cited study showed an 84% greater improvement in cognitive function (MoCA scores) for patients using the ABAStroke application compared to standard care alone [ICT&health, May 2024].

Data Accuracy: YELLOW -- The clinical result is cited by a trade publication. The business model and technological approach are consistently described across multiple sources.

Sources

Articles about ABAStroke

Related companies

Topics

View on Startuply.vc